Who Pays My Doctor?

Healthcare provider profile · identity verified

Saurabh Singh, MD

Allopathic & Osteopathic Physicians|Dermatology · FAIRFAX, VA · NPI 1275790925

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Saurabh Singh, MD received $516,291.75 in general payments during 2025 across 857 reported records.

Galderma Laboratories, L.P. accounted for 14.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 34 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jublia, Opzelura, Otezla, Rinvoq, Siliq, Vtama, Zoryve.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rinvoq by this doctor in 2024.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.

Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zoryve by this doctor in 2024.

Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Opzelura by this doctor in 2024.

Kowa Pharmaceuticals America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZORYVE as an associated drug or biological on 22731 records involving 10996 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zoryve by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OLUMIANT as an associated drug or biological on 560 records involving 277 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Olumiant by this doctor in 2024.

Organon LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VTAMA as an associated drug or biological on 29859 records involving 10220 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vtama by this doctor in 2024.

Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JUBLIA as an associated drug or biological on 5397 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jublia by this doctor in 2024.

Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SILIQ as an associated drug or biological on 3812 records involving 2101 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Siliq by this doctor in 2024.

Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SILIQ as an associated drug or biological on 24 records involving 20 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Siliq by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$516,291.75

857 reported records · 27 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $74,544.0514.4%982025
Lilly USA, LLC Unresolved — no canonical attribution shown $70,898.7013.7%1092025
GENZYME CORPORATION Unresolved — no canonical attribution shown $55,918.3710.8%602025
ABBVIE INC. Unresolved — no canonical attribution shown $51,697.0010.0%1112025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $48,461.669.4%632025
Botanix SB Inc Unresolved — no canonical attribution shown $42,492.218.2%452025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $40,556.247.9%452025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $39,715.547.7%742025
PFIZER INC. Unresolved — no canonical attribution shown $27,996.105.4%562025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $23,302.904.5%442025
Organon LLC Unresolved — no canonical attribution shown $20,443.024.0%272025
Amgen Inc. Unresolved — no canonical attribution shown $15,281.923.0%82025
Journey Medical Corporation Unresolved — no canonical attribution shown $1,613.780.3%42025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $699.260.1%342025
Kowa Pharmaceuticals America, Inc. Unresolved — no canonical attribution shown $650.000.1%12025
UCB, Inc. Unresolved — no canonical attribution shown $615.080.1%192025
Incyte Corporation Unresolved — no canonical attribution shown $515.280.1%222025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $341.650.1%162025
LEO Pharma Inc. Unresolved — no canonical attribution shown $201.200.0%72025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $96.240.0%32025
Regeneron Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $79.060.0%12025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $48.440.0%22025
Medimetriks Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $36.240.0%22025
Salix Pharmaceuticals, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $35.770.0%12025
STRATA Skin Sciences, Inc. Unresolved — no canonical attribution shown $28.100.0%32025
Astellas Pharma Global Development Unresolved — no canonical attribution shown $13.930.0%12025
Kerecis Limited Unresolved — no canonical attribution shown $10.010.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$378,629.64116
Compensation for serving as faculty or as a speaker for a medical education program$41,872.0013
Travel and Lodging$30,611.77156
Consulting Fee$29,852.5011
Honoraria$18,400.005
Food and Beverage$16,808.83554
Education$117.012

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. $95,593.26 130 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $67,640.51 90 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Lilly USA, LLC $66,106.15 99 2025
Source payment records
ILUMYA
Normalized: ilumya		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $48,382.77 50 2025
Source payment records
SOFDRA
Normalized: sofdra		 Drug Botanix SB Inc $42,492.21 45 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $38,206.24 44 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $30,874.53 61 2025
Source payment records
ZORYVE
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. $23,952.90 45 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $20,899.55 50 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $20,309.34 21 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $17,188.46 52 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $15,281.92 8 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $11,344.45 43 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc. $699.26 34 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $615.08 19 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $515.28 22 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $312.48 15 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $129.44 12 2025
Source payment records
LIBTAYO
Normalized: libtayo		 Biological Regeneron Healthcare Solutions, Inc. $119.71 5 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $111.11 5 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Drug Boehringer Ingelheim Pharmaceuticals, Inc. $96.24 3 2025
Source payment records
SILIQ
Normalized: siliq		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC, Salix Pharmaceuticals, a division of Bausch Health US, LLC $59.92 2 2025
Source payment records
  • 2025-03-10 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $35.77 · Open Payments source
  • 2025-04-14 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.15 · Open Payments source
Winlevi
Normalized: winlevi		 Drug SUN PHARMACEUTICAL INDUSTRIES INC. $58.43 11 2025
Source payment records
Cabtreo
Normalized: cabtreo		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $48.44 2 2025
Source payment records
  • 2025-04-14 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.15 · Open Payments source
  • 2025-12-01 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.29 · Open Payments source
AKLIEF
Normalized: aklief		 Drug Galderma Laboratories, L.P. $36.00 2 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $29.17 1 2025
Source payment records
XTRAC
Normalized: xtrac		 Device STRATA Skin Sciences, Inc. $28.10 3 2025
Source payment records
JUBLIA
Normalized: jublia		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $24.15 1 2025
Source payment records
  • 2025-04-14 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.15 · Open Payments source
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $23.87 1 2025
Source payment records
BOTOX
Normalized: botox		 Biological ABBVIE INC. $23.08 1 2025
Source payment records
Izervay
Normalized: izervay		 Drug Astellas Pharma Global Development $13.93 1 2025
Source payment records
Kerecis GraftGuide
Normalized: kerecis graftguide		 Device Kerecis Limited $10.01 1 2025
Source payment records
Kerecis SurgiClose
Normalized: kerecis surgiclose		 Device Kerecis Limited $10.01 1 2025
Source payment records
Leqselvi
Normalized: leqselvi		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $7.58 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
JUBLIA
jublia		 2025 Jublia 2024 34 exact normalized Medicare Part D
OPZELURA
opzelura		 2025 Opzelura 2024 15
Beneficiary count suppressed		 exact normalized Medicare Part D
OTEZLA
otezla		 2025 Otezla 2024 16
Beneficiary count suppressed		 exact normalized Medicare Part D
RINVOQ
rinvoq		 2025 Rinvoq 2024 22
Beneficiary count suppressed		 exact normalized Medicare Part D
SILIQ
siliq		 2025 Siliq 2024 13
Beneficiary count suppressed		 exact normalized Medicare Part D
VTAMA
vtama		 2025 Vtama 2024 15
Beneficiary count suppressed		 exact normalized Medicare Part D
ZORYVE
zoryve		 2025 Zoryve 2024 21 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 RINVOQ
open payments reported associated product		 CMS Open Payments — General Payments
279238 supporting records · 34343 recipient NPIs · example record 1201352600 		Rinvoq · 2024
Exact normalized brand match · 1 Part D row		 22 suppressed by CMS
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 OTEZLA
open payments reported associated product		 CMS Open Payments — General Payments
177267 supporting records · 48600 recipient NPIs · example record 1226871616 		Otezla · 2024
Exact normalized brand match · 1 Part D row		 16 suppressed by CMS
Arcutis Biotherapeutics, Inc.
Exact reporting entity; no affiliate inference		 2025 Zoryve
open payments reported associated product		 CMS Open Payments — General Payments
56906 supporting records · 10745 recipient NPIs · example record 1252324094 		Zoryve · 2024
Exact normalized brand match · 1 Part D row		 21 13
Incyte Corporation
Exact reporting entity; no affiliate inference		 2025 OPZELURA
open payments reported associated product		 CMS Open Payments — General Payments
59568 supporting records · 12571 recipient NPIs · example record 1225959946 		Opzelura · 2024
Exact normalized brand match · 1 Part D row		 15 suppressed by CMS
Kowa Pharmaceuticals America, Inc.
Exact reporting entity; no affiliate inference		 2025 ZORYVE
open payments reported associated product		 CMS Open Payments — General Payments
22731 supporting records · 10996 recipient NPIs · example record 1243071225 		Zoryve · 2024
Exact normalized brand match · 1 Part D row		 21 13
Lilly USA, LLC
Exact reporting entity; no affiliate inference		 2025 OLUMIANT
open payments reported associated product		 CMS Open Payments — General Payments
560 supporting records · 277 recipient NPIs · example record 1186464669 		Olumiant · 2024
Exact normalized brand match · 1 Part D row		 23 suppressed by CMS
Organon LLC
Exact reporting entity; no affiliate inference		 2025 VTAMA
open payments reported associated product		 CMS Open Payments — General Payments
29859 supporting records · 10220 recipient NPIs · example record 1237634330 		Vtama · 2024
Exact normalized brand match · 1 Part D row		 15 suppressed by CMS
Ortho Dermatologics, a division of Bausch Health US, LLC
Exact reporting entity; no affiliate inference		 2025 JUBLIA
open payments reported associated product		 CMS Open Payments — General Payments
5397 supporting records · 2963 recipient NPIs · example record 1220077864 		Jublia · 2024
Exact normalized brand match · 1 Part D row		 34 13
Ortho Dermatologics, a division of Bausch Health US, LLC
Exact reporting entity; no affiliate inference		 2025 SILIQ
open payments reported associated product		 CMS Open Payments — General Payments
3812 supporting records · 2101 recipient NPIs · example record 1220077864 		Siliq · 2024
Exact normalized brand match · 1 Part D row		 13 suppressed by CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC
Exact reporting entity; no affiliate inference		 2025 SILIQ
open payments reported associated product		 CMS Open Payments — General Payments
24 supporting records · 20 recipient NPIs · example record 1231787668 		Siliq · 2024
Exact normalized brand match · 1 Part D row		 13 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Triamcinolone AcetonideTriamcinolone Acetonide226116
Clobetasol PropionateClobetasol Propionate18997
MinoxidilMinoxidil14553
FluocinonideFluocinonide12176
MupirocinMupirocin10789
Clindamycin PhosphateClindamycin Phosphate6134
KetoconazoleKetoconazole5928
TacrolimusTacrolimus5938
Dupixent PenDupilumab53suppressed
Lidocaine-PrilocaineLidocaine/Prilocaine4529
Econazole NitrateEconazole Nitrate4427
FinasterideFinasteride4213
FluconazoleFluconazole3630
Doxycycline MonohydrateDoxycycline Monohydrate3415
JubliaEfinaconazole3413
ValacyclovirValacyclovir Hcl3320
Skyrizi PenRisankizumab-Rzaa27suppressed
GabapentinGabapentin25suppressed
Mometasone FuroateMometasone Furoate2417
OlumiantBaricitinib23suppressed
IvermectinIvermectin22suppressed
RinvoqUpadacitinib22suppressed
Levocetirizine DihydrochlorideLevocetirizine Dihydrochloride21suppressed
PimecrolimusPimecrolimus2116
ZoryveRoflumilast2113
Hydroxychloroquine SulfateHydroxychloroquine Sulfate18suppressed
MethotrexateMethotrexate Sodium17suppressed
TretinoinTretinoin17suppressed
NystatinNystatin16suppressed
OtezlaApremilast16suppressed
OpzeluraRuxolitinib Phosphate15suppressed
VtamaTapinarof15suppressed
Hydroxyzine HclHydroxyzine Hcl14suppressed
PrednisonePrednisone14suppressed
MetronidazoleMetronidazole13suppressed
SiliqBrodalumab13suppressed
FluorouracilFluorouracil12suppressed
CiclopiroxCiclopirox11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $516,291.75 · 857 records Galderma Laboratories, L.P. ADBRY, AKLIEF, ANZUPGO, BOTOX, Bimzelx, CIBINQO, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, ILUMYA, Izervay, JUBLIA, Kerecis GraftGuide, Kerecis SurgiClose, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SILIQ, SKYRIZI, SOFDRA, SPEVIGO, Sotyktu, TALTZ, TREMFYA, VTAMA, Winlevi, XTRAC, ZORYVE 10 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error